The DOI matches its Crossref record; 224 of the 224 references it cites were found in a registry or an index.
Lipid-Lowering Agents: Targets Beyond PCSK9
Abstract
Several new or emerging drugs for dyslipidemia owe their existence, in part, to human genetic evidence, such as observations in families with rare genetic disorders or in Mendelian randomization studies. Much effort has been directed to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and Lp[a] (lipoprotein[a]), with some sustained programs on agents to raise HDL (high-density lipoprotein) cholesterol. Lomitapide, mipomersen, AAV8.TBG.hLDLR, inclisiran, bempedoic acid, and gemcabene primarily target LDL cholesterol. Alipogene tiparvovec, pradigastat, and volanesorsen primarily target elevated triglycerides, whereas evinacumab and IONIS-ANGPTL3-L Rx target both LDL cholesterol and triglyceride. IONIS-APO(a)-L Rx targets Lp(a).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, substantial residual risk remains, for which numerous promising therapeutic targets are under investigation.11”
From Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70 (2022) · cites this paper as [11]
Citations
Cites
Items 201–224 of 224
Jowett, N. I., Rees, A., Williams, L. G., Stocks, J., Vella, M. A., Hitman, G. A., Katz, J., & Galton, D. J. (1984) · Diabetologia · doi:10.1007/bf00273802 · Cited by 26
CETP Inhibitors — A New Inning?
Hegele, R. A. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711407 · Cited by 23
Self-citationSrivastava, R. A. K., Cornicelli, J. A., Markham, B. E., & Bisgaier, C. L. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3353-5 · Cited by 22
Gaudet, D., DIGENIO, A. G., Alexander, V., Arca, M., Jones, A. F., Stroes, E. S. G., Bergeron, J., Civeira, F., Hemphill, L., Blom, D. J., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.06.059 · Cited by 22
Self-citationEffects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol
Karmaus, P. W. F., Shi, M. Y., Perl, S., Biancotto, A., Candia, J., Cheung, F., Kotliarov, Y., Young, N. S., & Fessler, M. B. (2019) · JCI Insight · doi:10.1172/jci.insight.131530 · Cited by 21
Gentile, M., Iannuzzi, A., Giallauria, F., D’Andrea, A., Venturini, E., Pacileo, M., Covetti, G., Panico, C., Mattiello, A., Vitale, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051422 · Cited by 21
Gouni-Berthold, I., Alexander, V., Digenio, A., DuFour, R., Steinhagen-Thiessen, E., Martin, S., Moriarty, P., Hughes, S., Jones, R., Witztum, J. L., et al. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.08.003 · Cited by 21
Apolipoprotein A-V gene therapy for disease prevention/treatment: a critical analysis
Trudy, M., Vineeta, S., & Robert, O. (2016) · The Journal of Biomedical Research · doi:10.7555/jbr.30.20150059 · Cited by 18
The future of n-3 polyunsaturated fatty acid therapy
Davidson, M. H., & Benes, L. B. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000353 · Cited by 18
Bisgaier, C. L., Oniciu, D. C., & Srivastava, R. A. K. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000580 · Cited by 17
Alexander, V. J., DIGENIO, A. G., Xia, S., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(18)32265-4 · Cited by 16
Brautbar, A., Virani, S. S., Belmont, J. W., Nambi, V., Jones, P. H., & Ballantyne, C. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m020404 · Cited by 14
HDL infusion for the management of atherosclerosis: current developments and new directions
Zheng, K. H., & Stroes, E. S. G. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000349 · Cited by 14
AAV1-LPLS447X gene therapy reduces hypertriglyceridemia in apoE2 knock in mice
Rip, J., van Dijk, K. W., Sierts, J. A., Kastelein, J. J. P., Twisk, J., & Kuivenhoven, J. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.08.008 · Cited by 11
Barriers to the Implementation of Lipoprotein Apheresis in Canada
Filler, G., Lee, M., & Hegele, R. A. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.01.008 · Cited by 11
Self-citationNew oral agents for treating dyslipidemia
Gryn, S. E., & Hegele, R. A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000354 · Cited by 9
Self-citationGenetics for the Identification of Lipid Targets Beyond PCSK9
Wang, L. R., & Hegele, R. A. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.003 · Cited by 8
Self-citationMakino, H., Tamanaha, T., & Harada‐Shiba, M. (2017) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2017.08.014 · Cited by 8
Srivastava, R. A. K., Cornicelli, J. A., Markham, B. E., & Bisgaier, C. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00471 · Cited by 8
Novel lipid-modifying therapies addressing unmet needs in cardiovascular disease
Kosmas, C. E., Sourlas, A., Silverio, D., Montan, P. D., & Guzman, E. (2019) · World Journal of Cardiology · doi:10.4330/wjc.v11.i11.256 · Cited by 8
Stefanutti, C. (2017) · PubMed · doi:10.2450/2016.0272-15 · Cited by 6
Gelrud, A., DIGENIO, A. G., Alexander, V. J., et al. (2018) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2018.04.476 · Cited by 5
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2018.08.194 · Cited by 4
Self-citationCan one overcome “unhealthy genes”?
Lazarte, J., & Hegele, R. A. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0099-2 · Cited by 3
Self-citation
Research works printed but not linked: 2
- 10.1194/jlr.P065334 · DOI
- 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Bergmark, B. A., Marston, N. A., Bramson, C. R., Curto, M., Ramos, V., Jevne, A., Kuder, J. F., Park, J.-G., Murphy, S. A., Verma, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059266 · Cited by 216
Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204
Self-citationThe dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association
Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.011 · Cited by 148
Self-citationElshazly, M. B., Mani, P., Nissen, S., Brennan, D. M., Clark, D., Martin, S., Jones, S. R., Quispe, R., Donnellan, E., Nicholls, S. J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319887578 · Cited by 103
Metadata
- Authors
- Hegele, R. A., & Tsimikas, S.
- Affiliations
- Western University (CA)
- University of California San Diego (US)
- Corresponding author
- Hegele, Robert A.
- Venue
- Circulation Research
- Published
- 2019-02
- Volume
- 124
- Issue
- 3
- Pages
- 386-404
- ISSN
- 0009-7330 (ISSN-L)
- 1524-4571
- OpenAlex
- W2914063169
- Cited by
- 171
- References
- 224
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 15 · 2023: 18 · 2022: 19 · 2021: 30 · 2020: 40 · 2019: 24
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-10-22)
- Open access
- closed
- Locations
- Circulation Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- National Heart, Lung, and Blood Institute (R01HL106579, R01HL078610, P01HL055798, R01HL124174, P01HL088093)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- lipid-lowering drugs, dyslipidemia, LDL cholesterol, triglycerides, lipoprotein(a), HDL cholesterol, lomitapide, mipomersen, inclisiran, bempedoic acid, volanesorsen, evinacumab, genetic evidence, Mendelian randomization, rare genetic disorders
- MeSH terms
- Ezetimibe, Antibodies, Monoclonal, Anticholesteremic Agents, Hypolipidemic Agents, Benzimidazoles, Caproates, Dicarboxylic Acids, Fatty Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Oligonucleotides, Hypertriglyceridemia, Genetic Therapy, Lipoprotein(a), RNA, Small Interfering, Dyslipidemias, Diacylglycerol O-Acyltransferase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
